Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?

Sales of Biogen’s (BIIB) key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is resulting in declining total revenues. Biogen’s total revenues declined 2% in 2024. In 2025, total revenues are expected to decline by a mid-single-digit percentage in constant currency terms.Biogen believes that some of its new drugs, Eisai-partnered Leqembi for Alzheimer’s disease, Skyclarys for Friedreich’s atax ...